Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Group 1 Mavacamten	0	18
Total, all-cause mortality	Group 2 Mavacamten	0	21
Total, all-cause mortality	Combined MAVA Treatment Group (Group 1+ Group 2)	0	39
Total, all-cause mortality	Placebo	0	19
Total, other adverse events	Group 1 Mavacamten	16	18
Total, other adverse events	Group 2 Mavacamten	18	21
Total, other adverse events	Combined MAVA Treatment Group (Group 1+ Group 2)	34	39
Total, other adverse events	Placebo	11	19
Total, serious adverse events	Group 1 Mavacamten	2	18
Total, serious adverse events	Group 2 Mavacamten	2	21
Total, serious adverse events	Combined MAVA Treatment Group (Group 1+ Group 2)	4	39
Total, serious adverse events	Placebo	4	19

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03442764/event-totals